Abstract
We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.
Original language | English |
---|---|
Pages (from-to) | 29-30 |
Number of pages | 2 |
Journal | Lancet (London, England) |
Volume | 345 |
Issue number | 8941 |
Publication status | Published - 7 Jan 1995 |
Keywords
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Breast Neoplasms
- Drug Tolerance
- Estradiol
- Estrogen Antagonists
- Female
- Humans
- Injections, Intramuscular
- Tamoxifen
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't